Immunic, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 93.61 million compared to USD 120.41 million a year ago. Basic loss per share from continuing operations was USD 2.11 compared to USD 3.78 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.28 USD | +1.99% | -7.25% | -14.67% |
May. 08 | Transcript : Immunic, Inc., Q1 2024 Earnings Call, May 08, 2024 | |
May. 08 | Immunic, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-14.67% | 113M | |
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |
- Stock Market
- Equities
- IMUX Stock
- News Immunic, Inc.
- Immunic, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023